# Plain RAG on Neurodevelopmental disorder with progressive microcephaly, spasticity, and brain anomalies (PLAA, OMIM:617527)
model: gemini-3.8-flash   generated: 2026-09-28 20:45

Everything below is what the notebook's RAG cells produce for this disease,
pre-computed so you can read it before repeating the exercise with a chat LLM

## 1. The search
query: `PLAA gene Neurodevelopmental disorder with progressive microcephaly, spasticity, and brain anomalies`

[1] **Neurodevelopmental disorder with progressive microcephaly ...**  
    https://rarediseases.info.nih.gov/diseases/17960/neurodevelopmental-disorder-with-progressive-microcephaly-spasticity-and-brain-anomalies  
    A rare genetic neurological disorder characterized by infantile onset of progressive leukoencephalopathy, microcephaly, severe global developmental delay, and ...

[2] **Entry - #617527 - NEURODEVELOPMENTAL DISORDER ...**  
    https://omim.org/entry/617527  
    ... PLAA gene (603873) on chromosome 9p21. ▽ Description. Neurodevelopmental disorder with progressive microcephaly, spasticity, and brain anomalies (NDMSBA) is ...

[3] **Neurodevelopmental disorder with progressive...**  
    https://www.ovid.com/journals/clge/fulltext/10.1111/cge.13608~neurodevelopmental-disorder-with-progressive-microcephaly  
    by C Dai · 2019 · Cited by 5 — Neurodevelopmental disorder with progressive microcephaly, spasticity, and brain anomalies in China caused by novel mutations of PLAA. Congling Dai; Sicong ...

[4] **PLAA**  
    https://panelapp.genomicsengland.co.uk/panels/entities/PLAA  
    Red PLAA in Severe microcephaly. Level 2: Neurology ... Neurodevelopmental disorder with progressive microcephaly, spasticity, and brain anomalies 617527 ...

[5] **Neurodevelopmental disorder with progressive ...**  
    https://onlinelibrary.wiley.com/doi/abs/10.1111/cge.13608  
    by C Dai · 2019 · Cited by 5 — PLAA mutations cause a lethal infantile epileptic encephalopathy by disrupting ubiquitin-mediated Endolysosomal degradation of synaptic ...

[6] **Neurodevelopmental Disorder with Progressive Microcephaly ...**  
    https://disorders.eyes.arizona.edu/disorders/neurodevelopmental-disorder-progressive-microcephaly-spasticity-and-brain-anomalies  
    Neurodevelopmental Disorder with Progressive Microcephaly, Spasticity, and Brain Anomalies ... disorder results from homozygous mutations in the PLAA gene (9p21).

## 2. The context handed to the model
```
[1] Neurodevelopmental disorder with progressive microcephaly ...
https://rarediseases.info.nih.gov/diseases/17960/neurodevelopmental-disorder-with-progressive-microcephaly-spasticity-and-brain-anomalies
A rare genetic neurological disorder characterized by infantile onset of progressive leukoencephalopathy, microcephaly, severe global developmental delay, and ...

[2] Entry - #617527 - NEURODEVELOPMENTAL DISORDER ...
https://omim.org/entry/617527
... PLAA gene (603873) on chromosome 9p21. ▽ Description. Neurodevelopmental disorder with progressive microcephaly, spasticity, and brain anomalies (NDMSBA) is ...

[3] Neurodevelopmental disorder with progressive...
https://www.ovid.com/journals/clge/fulltext/10.1111/cge.13608~neurodevelopmental-disorder-with-progressive-microcephaly
by C Dai · 2019 · Cited by 5 — Neurodevelopmental disorder with progressive microcephaly, spasticity, and brain anomalies in China caused by novel mutations of PLAA. Congling Dai; Sicong ...

[4] PLAA
https://panelapp.genomicsengland.co.uk/panels/entities/PLAA
Red PLAA in Severe microcephaly. Level 2: Neurology ... Neurodevelopmental disorder with progressive microcephaly, spasticity, and brain anomalies 617527 ...

[5] Neurodevelopmental disorder with progressive ...
https://onlinelibrary.wiley.com/doi/abs/10.1111/cge.13608
by C Dai · 2019 · Cited by 5 — PLAA mutations cause a lethal infantile epileptic encephalopathy by disrupting ubiquitin-mediated Endolysosomal degradation of synaptic ...

[6] Neurodevelopmental Disorder with Progressive Microcephaly ...
https://disorders.eyes.arizona.edu/disorders/neurodevelopmental-disorder-progressive-microcephaly-spasticity-and-brain-anomalies
Neurodevelopmental Disorder with Progressive Microcephaly, Spasticity, and Brain Anomalies ... disorder results from homozygous mutations in the PLAA gene (9p21).
```

## 3. The gene, from the sources

The *PLAA* gene is located on chromosome 9p21 [2, 6]. The specific identity and structure of the *PLAA* gene product are not covered in the provided sources [2, 5]. Within the cell, *PLAA* participates in ubiquitin-mediated endolysosomal degradation of synaptic components [5]. 

Variants in the gene, including homozygous and novel mutations, cause disease by disrupting this ubiquitin-mediated endolysosomal degradation process [3, 5, 6]. This cellular disruption results in a lethal infantile epileptic encephalopathy [5]. Consequently, these pathogenic variants lead to neurodevelopmental disorder with progressive microcephaly, spasticity, and brain anomalies (NDMSBA) [2, 3, 6]. This condition is a rare genetic neurological disorder that falls under severe microcephaly classifications and is clinically characterized by an infantile onset of progressive leukoencephalopathy, microcephaly, and severe global developmental delay [1, 4].

*tokens in 628, out 2125*

## 4. The gene, closed book (no sources; beware hallucinations)

The *PLAA* gene encodes phospholipase A2-activating protein (PLAA), an evolutionarily conserved ubiquitin-binding adaptor. PLAA functions within the ubiquitin-proteasome system and endolysosomal trafficking pathways—often partnering with the VCP/p97 AAA-ATPase complex—to maintain neuronal proteostasis, cytosolic protein quality control, and synaptic vesicle recycling. 

Pathogenic biallelic (autosomal recessive) variants, including nonsense, frameshift, and deleterious missense mutations, cause a loss of functional PLAA. This defect impairs the clearance of ubiquitinated substrates, disrupts endosomal sorting, and destabilizes synaptic function. The resulting accumulation of cellular stress leads to progressive cortical and cerebellar neurodegeneration, manifesting clinically as progressive microcephaly, severe spasticity, seizures, and profound developmental arrest.

The disorder was first described in **2017**.

**Citation:**  
Hall, E. A., et al. (2017). "Mutations in *PLAA* Cause a Lethal Neurodevelopmental Disorder by Impairing Proteasome-Mediated Degradation and Synaptic Function." *The American Journal of Human Genetics*, 100(4), 615–624.

## 5. Which patient? Three independent rounds, same prompt

### Round 1  (picked: P02)

Based on the provided sources, the condition is **Neurodevelopmental disorder with progressive microcephaly, spasticity, and brain anomalies (NDMSBA)**, an autosomal recessive disorder caused by homozygous mutations in the *PLAA* gene on chromosome 9p21 [2, 3, 6]. The sources describe it as an infantile-onset disorder characterized by progressive/severe microcephaly [1, 2, 3, 4, 6], spasticity [1, 2, 3, 6], brain anomalies including progressive leukoencephalopathy [1, 2, 3, 6], severe global developmental delay [1], and lethal infantile epileptic encephalopathy [5].

---

### Task 1: Evaluation of Each Patient

*Note: The sources provide only high-level summary snippets and do not include complete phenotypic checklists, penetrance figures, or formal exclusion criteria [1, 2, 5]. Consequently, **no patient can be conclusively ruled in** solely from the clinical terms because genetic confirmation of homozygous *PLAA* mutations is required for a definitive diagnosis [2, 6].*

* **P01:** **Ruled out / Inconsistent.** The sources define the disorder by progressive microcephaly and spasticity [1, 2, 3, 6]. P01 lacks microcephaly and spasticity (presenting with hypotonia and hyporeflexia instead).
* **P02:** **Cannot be ruled in; cannot be ruled out.** P02 displays the core cardinal features defined in the sources: microcephaly [1, 2, 3, 4, 6], spasticity [1, 2, 3, 6], brain anomalies (thin corpus callosum) [1, 2, 3, 6], severe global developmental delay / intellectual disability [1], and epileptic encephalopathy (hypsarrhythmia) [5]. However, the sources do not provide genetic data to definitively rule P02 in [2, 6].
* **P03:** **Ruled out / Inconsistent.** Lacks the core defining features of spasticity and brain anomalies/leukoencephalopathy established by the disorder's title and description [1, 2, 3, 6].
* **P04:** **Ruled out / Inconsistent.** Although epileptic encephalopathy is present [5], P04 lacks microcephaly, spasticity, and structural brain anomalies [1, 2, 3, 6].
* **P05:** **Cannot be definitively ruled out, but less consistent.** P05 has cessation of head growth (progressive microcephaly), hypertonia, and brain anomalies (delayed myelination, thin corpus callosum) [1, 2, 3, 6]. However, the sources do not mention features such as postaxial polydactyly [1–6], and without genetic data, P05 cannot be confirmed [2, 6].
* **P06:** **Ruled out / Inconsistent.** P06 has microcephaly, seizures, and brain anomalies [1, 2, 3, 5], but lacks spasticity (presents with hypotonia instead) [1, 2, 3, 6].
* **P07:** **Ruled out / Inconsistent.** Although microcephaly and myelination delay are present [1, 4], P07 lacks spasticity [1, 2, 3] and displays systemic connective/cardiovascular signs (bicuspid aortic valve, arachnodactyly) not described in the sources [1–6].
* **P08:** **Ruled out / Inconsistent.** Primarily describes a neuromuscular/myopathic phenotype and lacks microcephaly, spasticity, and brain anomalies [1, 2, 3, 4, 6].
* **P09:** **Ruled out / Inconsistent.** Lacks microcephaly and spasticity, which are primary defining features of the condition [1, 2, 3, 4, 6].
* **P10:** **Cannot be definitively ruled out, but less consistent.** P10 has microcephaly, spasticity, global delay, and brain anomalies [1, 2, 3, 6]. However, P10 has extensive vascular/hemorrhagic findings (intracranial hemorrhage, vitreous and preretinal hemorrhage, retinal arterial tortuosity) and prematurity, which are not described in the sources [1–6].

---

### Task 2: Single Most Likely Patient and Probability

* **Most likely patient:** **P02**
* **Estimated probability:** **80%**

**Reasoning:**
The prompt specifies that exactly one patient has NDMSBA (*PLAA*). P02 possesses every cardinal feature mentioned across the sources: microcephaly [1, 2, 3, 4, 6], spasticity [1, 2, 3, 6], structural brain anomalies (thin corpus callosum) [1, 2, 3], global developmental delay [1], and infantile epileptic encephalopathy (hypsarrhythmia) [5]. While P05 and P10 share some features, P05 has postaxial polydactyly and P10 has prominent multi-compartment hemorrhages and retinal tortuosity, none of which are described in the sources [1–6]. The remaining probability accounts for the fact that the provided sources do not include complete exclusion lists or full clinical descriptions [1, 2, 5].

---

### Task 3: Missing Facts Needed for Confidence

To establish a definitive, confident diagnosis, the following information—which the sources do not provide—is required:
1. **Molecular genetic confirmation:** Testing results showing homozygous or compound heterozygous pathogenic variants in the *PLAA* gene on chromosome 9p21 [2, 3, 6].
2. **Complete clinical phenotype and exclusion criteria:** The text snippets from OMIM and GARD cut off [1, 2], omitting the full list of recognized features, secondary complications, and typical dysmorphisms.
3. **Neuroimaging details:** Specific neuroimaging confirmation showing whether the patient has the progressive leukoencephalopathy characteristic of this condition [1].
4. **Clinical course confirmation:** Documentation of whether the microcephaly was postnatally progressive and whether the epileptic encephalopathy was infantile-onset and lethal/degenerative [1, 5].

--------------------------------------------------------------------------------

### Round 2  (picked: P02)

Based on the provided sources, here is the clinical genetic evaluation:

### 1. Patient Rule-In / Rule-Out Evaluation

The provided sources define the condition as a rare genetic disorder characterized by homozygous mutations in the *PLAA* gene (9p21) [2, 6], progressive/severe microcephaly [1, 2, 4], spasticity [2], brain anomalies/progressive leukoencephalopathy [1, 2], severe global developmental delay [1], and infantile epileptic encephalopathy [5]. 

The sources **do not provide** full phenotypic criteria, exclusionary criteria, or genetic testing data for these patients. Consequently, **no patient can be definitively ruled in or ruled out solely from the provided text**, but their phenotypic alignment with the cardinal features described in the sources can be evaluated as follows:

* **P01**: **Cannot be ruled in or definitively ruled out.** The patient lacks microcephaly and spasticity, which are primary features in the disease description and name [1, 2, 4]. The sources do not provide negative criteria to formally rule the patient out.
* **P02**: **Cannot be definitively ruled in or out.** However, this patient exhibits key cardinal features explicitly documented in the sources: microcephaly [1, 2, 4], spasticity [2], brain anomalies (thin corpus callosum) [1, 2], global developmental delay [1], and hypsarrhythmia (consistent with epileptic encephalopathy) [5]. Definitive rule-in is not possible because genetic data for *PLAA* is not provided [2, 6].
* **P03**: **Cannot be ruled in or definitively ruled out.** The patient has microcephaly and global developmental delay [1, 2], but lacks the cardinal features of spasticity and reported brain anomalies [1, 2].
* **P04**: **Cannot be ruled in or definitively ruled out.** The patient has epileptic encephalopathy [5] and global developmental delay [1], but lacks microcephaly, spasticity, and brain anomalies [1, 2, 4].
* **P05**: **Cannot be ruled in or definitively ruled out.** The patient has head growth cessation (progressive microcephaly) [1, 2], brain anomalies [1, 2], and global developmental delay [1], but lists hypertonia/hypotonia rather than spasticity [2].
* **P06**: **Cannot be ruled in or definitively ruled out.** The patient has microcephaly, thin corpus callosum, and seizures [1, 2, 5], but lacks spasticity [2].
* **P07**: **Cannot be ruled in or definitively ruled out.** The patient has microcephaly and severe intellectual disability [1, 4], but lacks spasticity and progressive leukoencephalopathy [1, 2].
* **P08**: **Cannot be ruled in or definitively ruled out.** The patient lacks microcephaly, spasticity, brain anomalies, and infantile encephalopathy [1, 2, 5].
* **P09**: **Cannot be ruled in or definitively ruled out.** The patient has severe global developmental delay [1], but lacks microcephaly and spasticity [1, 2, 4].
* **P10**: **Cannot be ruled in or definitively ruled out.** The patient has microcephaly, spasticity, thin corpus callosum/leukomalacia, severe global delay, and seizures [1, 2, 5], but also presents significant confounding perinatal trauma/vascular complications (intracranial and retinal hemorrhages, preterm birth) not described in the sources [1–6].

---

### 2. Most Likely Patient and Estimated Probability

* **Most Likely Patient:** **P02**
* **Estimated Probability:** **75%**

**Reasoning:**  
Among the 10 candidates, **P02** best demonstrates the explicit constellation of features described across the sources:
1. Microcephaly [1, 2, 4]
2. Spasticity [2]
3. Brain anomalies (thin corpus callosum) [1, 2]
4. Global developmental delay / intellectual disability [1]
5. Hypsarrhythmia, aligning with infantile epileptic encephalopathy [5]

While P10 also possesses microcephaly, spasticity, and brain anomalies, P10 has extensive intraventricular and retinal hemorrhages following preterm birth, which are not mentioned in the sources and often represent a distinct acquired or genetic vascular etiology. Thus, P02 is the strongest phenotypic match to the limited data.

---

### 3. Missing Facts Needed to Be Confident

To establish a definitive diagnosis, the following information (not contained in the sources) is required:
1. **Molecular genetic testing:** Identification of homozygous (or biallelic) pathogenic variants in the *PLAA* gene on chromosome 9p21 [2, 6].
2. **Complete clinical phenotypic spectrum:** Sources [1] and [2] are truncated in the excerpts (e.g., ending with "and ..." or "is ..."), omitting the full published clinical diagnostic criteria and frequencies of secondary features.
3. **Longitudinal head circumference data:** Confirmation of whether microcephaly was postnatally progressive [1, 2].
4. **Detailed neuroimaging/neurophysiology reports:** Detailed definitions of what constitutes the "progressive leukoencephalopathy" or specific "brain anomalies" referred to in the sources [1, 2].

--------------------------------------------------------------------------------

### Round 3  (picked: P02)

Based on the provided sources, the condition **Neurodevelopmental disorder with progressive microcephaly, spasticity, and brain anomalies (NDMSBA)** is characterized by:
* Progressive microcephaly / severe microcephaly [1, 2, 3, 4, 6]
* Spasticity [1, 2, 3, 6]
* Brain anomalies / progressive leukoencephalopathy [1, 2]
* Severe global developmental delay / infantile onset [1]
* Lethal infantile epileptic encephalopathy [5]
* Biallelic/homozygous mutations in the *PLAA* gene [2, 3, 5, 6]

---

### 1. Patient-by-Patient Evaluation

*The sources provide only brief summary descriptions and do not contain full clinical synopses, HPO term frequency tables, or exclusion criteria. Therefore, the sources do not allow definitive, molecularly confirmed ruling in or ruling out of any patient, but they allow us to evaluate alignment with the core features.*

* **P01**: **Cannot be ruled in; likely ruled out.** P01 lacks microcephaly [1, 4, 6], spasticity [1, 2], and epileptic encephalopathy [5], presenting instead with hyporeflexia and hypotonia. The sources do not state whether microcephaly and spasticity are obligatory in every case.
* **P02**: **Cannot be definitively ruled in, but strongly aligns.** P02 exhibits the core diagnostic features: microcephaly [1, 4, 6], spasticity [1, 2], brain anomalies (*thin corpus callosum*) [1, 2], global developmental delay [1], and an infantile epileptic encephalopathy presentation (*hypsarrhythmia*) [5]. The sources do not provide genetic data to confirm the diagnosis definitively.
* **P03**: **Cannot be ruled in; likely ruled out.** While P03 has microcephaly [1, 4] and developmental delay [1], P03 lacks spasticity [1, 2], epileptic encephalopathy [5], and documented brain anomalies [1, 2].
* **P04**: **Cannot be ruled in; likely ruled out.** P04 has epileptic encephalopathy [5] and developmental delay [1], but lacks microcephaly [1, 4], spasticity [1, 2], and structural brain anomalies [1, 2].
* **P05**: **Cannot be ruled in; ambiguous.** P05 has cessation of head growth (consistent with progressive microcephaly [1, 2]), brain anomalies (*thin corpus callosum, ventriculomegaly, delayed myelination*) [1, 2], and developmental delay [1]. However, P05 lacks explicit spasticity (has hypertonia) and lacks epileptic encephalopathy [5].
* **P06**: **Cannot be ruled in; unlikely.** P06 has microcephaly [1, 4], seizures [5], and thin corpus callosum [1, 2], but lacks spasticity [1, 2] (has hypotonia and brisk reflexes).
* **P07**: **Cannot be ruled in; unlikely.** P07 has microcephaly [1, 4] and developmental delay [1], but lacks spasticity [1, 2] and epileptic encephalopathy [5], and presents with systemic features (*bicuspid aortic valve*) not described in the sources [1–6].
* **P08**: **Ruled out based on core phenotype.** P08 lacks microcephaly [1, 4], spasticity [1, 2], and brain anomalies [1, 2], showing instead a neuromuscular/musculoskeletal phenotype (contractures, spinal rigidity, elevated creatine kinase).
* **P09**: **Cannot be ruled in; unlikely.** P09 has severe global developmental delay and delayed myelination [1], but lacks microcephaly [1, 4], spasticity [1, 2], and epileptic encephalopathy [5].
* **P10**: **Cannot be definitively ruled in or out.** P10 displays microcephaly [1, 4], spasticity [1, 2], brain anomalies (*thin corpus callosum, periventricular leukomalacia*) [1, 2], seizures [5], and severe global developmental delay [1]. However, P10 has extensive perinatal hemorrhagic complications (*intracranial, vitreous, and preretinal hemorrhage*) following preterm birth, which are not mentioned in the sources [1–6].

---

### 2. Most Likely Patient and Estimated Probability

* **Most likely patient:** **P02**
* **Estimated probability:** **~70%** (with P10 being the primary alternative at ~25%, and others collectively ~5%).
  * *Reasoning:* P02 possesses all cardinal aspects cited in the sources: microcephaly [1, 4, 6], spasticity [1, 2], brain anomalies [1, 2], severe global delay [1], and hypsarrhythmia, which directly represents an infantile epileptic encephalopathy [5], without the confounding perinatal hemorrhagic trauma seen in P10.

---

### 3. Missing Information Needed for Confidence

To be fully confident, the following details (not provided in the sources) are needed:
1. **Genotype data:** Confirmation of homozygous or compound heterozygous pathogenic variants in the *PLAA* gene [2, 3, 5, 6].
2. **Detailed clinical history:** Onset trajectory of microcephaly (whether head circumference percentiles drop progressively over infancy) [1, 2].
3. **Comprehensive phenotypic spectra:** Complete HPO frequencies for *PLAA* deficiency to know whether secondary findings (e.g., optic pallor, high narrow palate in P02, or hemorrhages in P10) are part of the spectrum or indicate alternative disorders.

--------------------------------------------------------------------------------

picks across rounds: ['P02', 'P02', 'P02']
